Peter Hecht’s $81M pledge to salvage Cyclerion assets nabs Polaris support
Peter Hecht and his crew are ready to reveal the name behind their new startup and disclose the identity of another VC investor behind their previously disclosed $81 million Series A.
The new biotech, Tisento Therapeutics, said Monday that Polaris is part of the syndicate behind its bid to revive a mid-stage rare disease asset out of Cyclerion Therapeutics. Polaris, a blue-chip life sciences firm that has also backed Cyclerion, joins Tisento’s syndicate of Invus, Hecht himself, Sanofi Ventures, Venrock, J. Wood Capital and other unnamed investors that were first unveiled in May.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
